指南与共识肥胖与代谢综合征糖尿病

EASO-EFAD-ECPO共识:成人肠促胰素治疗的营养、功能与心理考量

Nutritional, functional, and psychological considerations for incretin-based therapies in adults-an EASO, EFAD, and ECPO Consensus Statement.
指南 / 共识 · Lancet Diabetes Endocrinol · 2026-07-08

该共识由EASO、EFAD与ECPO制定,针对成人使用GLP-1受体激动剂及双GLP-1-GIP受体激动剂治疗肥胖,提出营养、功能与心理方面的实用考量。共识汇总医学营养治疗(含蛋白质目标、膳食质量、胃肠道不良反应缓解)、瘦体重与身体功能保护、心理筛查与整合支持、减重监测及公平性等推荐,并强调共同决策与未来研究方向。

要点

  • 减重期间关注蛋白质摄入与膳食质量,以缓解胃肠道不良反应并支持瘦体重保留。
  • 建议进行心理筛查,必要时提供整合支持,关注食物奖赏、应对方式与社会连接变化。
  • 减重监测包括膳食质量、微量营养素风险与功能指标,必要时评估身体成分。

核心结论

  • 肠促胰素治疗可带来显著减重与心脏代谢获益,但部分个体可能出现营养、功能或心理风险,需实用考量。
  • 共识提出营养、功能与心理方面的实用建议,并强调共同决策与公平性。

研究设计与样本

  • EASO、EFAD与ECPO共同制定的共识声明,综合证据并提出实用考量。

主要发现

  • 肠促胰素治疗(含GLP-1受体激动剂与双GLP-1-GIP受体激动剂)可产生显著减重与心脏代谢获益。
  • 食欲下降、快速减重、胃肠道不良反应及进食行为改变可能带来营养、功能或心理风险。

关键数值与推荐

  • 医学营养治疗包括减重期间的蛋白质目标、膳食质量及胃肠道不良反应缓解。
  • 建议充足蛋白质摄入与渐进性抗阻运动以帮助保留瘦体重与身体功能。
  • 推荐心理筛查,必要时提供整合支持。
  • 建议监测膳食质量、微量营养素风险与功能指标,必要时评估身体成分。
  • 推荐与患者共同决策起始、上调、延迟、暂停、下调或停用肠促胰素治疗。

临床怎么用

  • 在肠促胰素治疗中整合营养、功能与心理评估与支持。
  • 关注蛋白质摄入与抗阻运动,监测膳食质量、微量营养素风险与功能指标。
  • 与患者共同决策治疗调整,权衡治疗与否的生理与心理风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Incretin-based therapies, including GLP-1 receptor agonists and dual GLP-1-GIP receptor agonists, have transformed obesity management, producing substantial weight loss and cardiometabolic benefits, with potential improvements in obesity-related complications, physical function, quality of life, and psychological wellbeing for many individuals. However, reduced appetite, rapid weight loss, gastrointestinal adverse effects, and changes in eating behaviour might create nutritional, functional, or psychological risks in some individuals. This EASO-EFAD-ECPO Consensus Statement outlines pragmatic nutritional, functional, and psychological considerations during incretin-based therapy treatment. We synthesise evidence on medical nutrition therapy, including protein targets during weight loss, dietary quality, and mitigation of gastrointestinal adverse events. We discuss pragmatic approaches that could help support preservation of fat-free mass and physical function during weight loss, including adequate protein intake and progressive resistance exercise. We emphasise the psychological and identity-related challenges during incretin-based therapy, including shifts in food reward, coping, and social connection, and recommend psychological screening, with integrated support where needed. We propose pragmatic monitoring during weight loss, including diet quality, micronutrient risk, and functional measures, with body-composition assessment where indicated. We suggest approaches to address disparities in access and adherence to ensure equity. We discuss the importance of shared decision making with the patient in decisions to start, up-titrate, delay, pause, down-titrate, or discontinue incretin-based therapies, considering the physical and psychological risks of treating versus not treating. Finally, we identify future research priorities, including longitudinal research on micronutrient status, macronutrient requirements, changes in dietary patterns and food choices, musculoskeletal outcomes, unique dosing schedules, and post-cessation maintenance to optimise safety, efficacy, and the patient experience.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Dobbie LJ, Tolvanen L, Alves D, et al. Nutritional, functional, and psychological considerations for incretin-based therapies in adults-an EASO, EFAD, and ECPO Consensus Statement. Lancet Diabetes Endocrinol. 2026. PMID: 42419343. doi:10.1016/S2213-8587(26)00122-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。